Investor Relations

Investor Relations

Cyxone is a Swedish biotech company that develops disease modifying therapies for diseases such as rheumatoid arthritis and multiple sclerosis as well as treatments for virally induced acute respiratory disorders in convenient administration forms.

With three unique projects, all developing towards important and potentially value-creating milestones, Cyxone is well positioned to deliver consequential benefits for patients, the health care system as well as for its shareholders. Cyxone’s goal is to out-license projects to strong partners after Phase 2 clinical trials to maximize their potential.

Cyxone’s financial statements are prepared in accordance with International Financial Reporting Standards (IFRS) issued by the International Accounting Standards Board (IASB) as adopted by the EU.

Download Cyxone’s Significant Accounting Principles as PDF

Investor Relations contact
Tara Heitner, CEO

Latest Press Release

Financial Calendar

Silent period Q2, 2021

Start date: 28 July 2021

End date: 27 August 2021

The half-year report 2021 will be published on 27 August and the silent period starts 28 July 2021.

Half-year report 2021

Date: 27 August 2021

Silent period Q3 2021

Start date: 13 October 2021

End date: 12 November 2021

The interim report for Q3 2021 will be published on 12 November 2021 and the silent period starts 13 October 2021.